Compare Honeywell International Inc (HON) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Honeywell International Inc vs Sanofi SA — how do they compare? Honeywell International Inc trades at $207.77 (market cap $65.48B), while Sanofi SA trades at $40.04 (market cap $95.18B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Honeywell International Inc for 91 Days and Sanofi SA for 94 Days on average.
| HON | SNY | |
|---|---|---|
Market Cap | $65.48B | $95.18B |
Volume | 2,047,782 | 2,995,646 |
Sector | Industrials | Health |
52-Week High | $248.79 | $52.34 |
52-Week Low | $188.14 | $39.51 |
Typical Hold Time | 91 Days | 94 Days |
Enterprise Value | $90.27B | $114.48B |
Dividend Yield | 1.36% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Honeywell International (HON) trades at $208.12 with minimal daily movement, showing strong profitability metrics including 21.6% net margin and 47.4% ROE. The company recently completed a strategic split into three focused businesses and secured a $300 million refinery project, positioning for growth in automation. Technical indicators show bearish momentum with support at $205 and resistance at $208, while fundamentals reveal attractive valuation with P/E of 7.9x below industry averages.
HON presents a compelling value opportunity with analyst consensus target of $259.25 representing 25% upside potential. The company's post-spin growth story is gaining momentum with recent earnings beats, though investors should monitor debt levels that have increased to 47.7% of assets and potential execution risks from the corporate restructuring.
SNY trades at $40.17, down slightly by 0.07%. The technical outlook is bearish, with price near key support at $40. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21, and revenue for 2025 reached $46.72B. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling growth potential beyond its blockbuster drug Dupixent.
The stock presents a mixed outlook. Positive factors include consistent earnings beats, a high gross margin of 72.77%, and strategic partnerships. However, a bearish technical signal, a projected net income decline to $4.0B in 2026, and a high proportion of analyst hold ratings (51.86%) suggest caution. Key risks involve execution of new drug pipelines and future patent expirations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Honeywell International Inc
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
